Head-to-head · Value Score
Trimi Health vs Spry
Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, Spry a 65. Here's who gives you the honest lower price — and where each one bites back.
Trimi Health
#3 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameSpry
#318 · Grade C · Watch List
Est. first month
From $199/mo (starting dose, compounded)
Save ~85% vs brand-nameThe verdict
Trimi Health takes it on Value Score, 89 to 65 — an est. $99/mo first month, with no teaser step-up baked in. Spry isn't out of it: Shoppers who want compounded GLP-1 plus anti-aging peptides under one membership.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Trimi Health | Spry |
|---|---|---|
| Value Score | 89 (A) | 65 (C) |
| Est. first month | $99/mo | From $199/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~85% |
| Semaglutide | $99/mo | From $199/mo (starting dose, compounded) |
| Tirzepatide | $125/mo | From $299/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Trimi Health
The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.
Why it's a deal
- Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
- Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
- Nationwide 50-state reach, so the low price isn't gated to a handful of states
The fine print
- Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
- Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
- Newer brand with a thin public track record
Spry
Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo).
Why it's a deal
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
The fine print
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Trimi Health is ranked on the Trimi Health alternatives board, and the same list for the other side is on alternatives to Spry.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.